João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior
{"title":"免疫治疗和局部治疗在转移性喉癌的治疗：1例报告。","authors":"João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior","doi":"10.3332/ecancer.2025.1947","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.</p><p><strong>Methods: </strong>We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.</p><p><strong>Results: </strong>The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.</p><p><strong>Conclusion: </strong>The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1947"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426497/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report.\",\"authors\":\"João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior\",\"doi\":\"10.3332/ecancer.2025.1947\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.</p><p><strong>Methods: </strong>We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.</p><p><strong>Results: </strong>The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.</p><p><strong>Conclusion: </strong>The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.</p>\",\"PeriodicalId\":11460,\"journal\":{\"name\":\"ecancermedicalscience\",\"volume\":\"19 \",\"pages\":\"1947\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426497/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ecancermedicalscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3332/ecancer.2025.1947\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2025.1947","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report.
Background: Advanced laryngeal carcinoma (LC) has a poor prognosis with limited treatment options. Managing oligometastasis is challenging, and there are currently no standard recommendations.
Methods: We reported a case of a 64-year-old male with locally advanced LC who developed oligometastatic disease in the bones and liver 21 months after concurrent cisplatin-based chemoradiotherapy. Initially, due to negative PD-L1 expression, the patient was treated docetaxel, cisplatin and cetuximab combination. Chemotherapy after 10 months, new hepatic progression was confirmed by biopsy. Given the asymptomatic, single-site progression in a cirrhotic liver, microwave ablation was performed. Isolated bone progressions were treated with stereotactic body radiation therapy at 2 and 4 months, and nivolumab replaced cetuximab.
Results: The patient has shown no evidence of disease progression for 22 months, with excellent tolerance.
Conclusion: The synergy between nivolumab and local therapies appears promising for managing oligometastasis in laryngeal cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
